Your browser doesn't support javascript.
loading
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.
Barberio, Brigida; Savarino, Edoardo Vincenzo; Card, Timothy; Canova, Cristina; Baldisser, Francesco; Gubbiotti, Alessandro; Massimi, Davide; Ghisa, Matteo; Zingone, Fabiana.
Afiliación
  • Barberio B; Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
  • Savarino EV; Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
  • Card T; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.
  • Canova C; Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK.
  • Baldisser F; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK.
  • Gubbiotti A; Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • Massimi D; Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
  • Ghisa M; Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
  • Zingone F; Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padua, Italy.
Intest Res ; 20(1): 114-123, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34333908
BACKGROUND/AIMS: Current literature is lacking in studies comparing the incidence of adverse events (AEs) in patients with inflammatory bowel diseases (IBD) treated with adalimumab (ADA) or vedolizumab (VDZ) in a real-life scenario. Therefore, our primary aim was to compare the AEs occurring in patients taking ADA to those of patients taking VDZ. METHODS: In this single center study, data on AEs from IBD patients who underwent treatment with ADA and VDZ were retrospectively collected. AE rates per 100 person-years were calculated. A Cox regression model was used to estimate the hazard ratios of the AEs between the 2 drugs. RESULTS: A total of 16 ADA patients (17.2%) and 11 VDZ patients (7.6%) had AEs causing drug interruption during the study period (P=0.02). Most of the AEs were noninfectious extraintestinal events (50% in ADA and 54.5% in VDZ) while infections accounted for 31.2% of the AEs in patients treated with ADA and 27.3% in those treated with VDZ. The incidence rate of AEs causing withdrawal of therapy was 13.2 per 100 person-years for ADA and 5.3 per 100 person-years for VDZ, corresponding to a 76% lower risk in patients in VDZ. Considering the first year of treatment, we observed 34 subjects treated with ADA (36.5%) having at least 1 AEs and 57 (39.3%) among those taking VDZ (P=0.67). CONCLUSIONS: VDZ has a lower incidence rate of AEs causing withdrawal of treatment compared to ADA but a similar risk of AEs not causing drug interruption. Real-life head-to-head studies are still necessary to further explore the safety profile of these drugs.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Incidence_studies / Risk_factors_studies Idioma: En Revista: Intest Res Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Incidence_studies / Risk_factors_studies Idioma: En Revista: Intest Res Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Corea del Sur